InMed Pharmaceuticals Inc. Common Shares

Day range

$1.41 – $1.62

Open

$1.44

Prev close

$1.44

Volume

231.58K

Market cap

$7.91M

Shares out

5.49M

P/E

—

P/S

4.08

P/B

7.36

P/FCF

—

ROE

-1208.6%

ROA

-428.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Merger agreementSep 18, 2026

  The decline in the Company's shareholders' equity is attributable largely to transaction-related expenses accrued in connection with the Company's previously announced Agreement and Plan of Merger and Reorganization dated May 19, 2026 ... entered into with Mentari Therapeutics, Inc. ... pursuant to which, among other things, the Company will merge with Mentari (the "Merger").

• Private placementJul 22, 2026

  On July 22, 2026, Mentari entered into Amendment No. 1 to the Securities Purchase Agreement (the "Amendment") with certain of the Original Investors and certain additional investors (the "New Investors"), pursuant to which they agreed to purchase, immediately prior to the First Effective Time, an aggregate of $200 million in additional shares of Mentari's common stock (the "Additional Shares") and/or additional pre-funded warrants to purchase shares of Mentari's common stock

• Merger agreementJul 10, 2026

  On July 6, 2026, InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the "Company"), Indigo Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of the Company (the "First Merger Sub"), Indigo Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (the "Second Merger Sub" and, together with First Merger Sub, the "Merger Subs"), and Mentari Therapeutics, Inc., a Delaware corporation ("Mentari"), entered into Amendment No. 1 to the Agreement and Plan of Merger and Reorganization (the "Amendment"), which amends the Agreement and Plan of Merger and Reorganization, dated as of May 19, 2026 (as amended, the "Merger Agreement").

• Listing compliance regainedJun 10, 2026

  On June 3, 2026, the Company received written notice from Nasdaq informing the Company that, for the 10 consecutive business days from May 19, 2026 through June 2, 2026, the closing bid price of the Company's common shares had been at or above $1.00 per share. Accordingly, the Company has regained compliance with the Bid Price Requirement and Nasdaq has advised the Company that this matter is now closed.

• Merger agreementMay 19, 2026

  On May 19, 2026, InMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia (the "Company"), Indigo Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of the Company (the "First Merger Sub"), Indigo Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (the "Second Merger Sub" and, together with First Merger Sub, the "Merger Subs"), and Mentari Therapeutics, Inc., a Delaware corporation ("Mentari"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, (i) the First Merger Sub will merge with and into Mentari, with Mentari surviving the merger as a wholly owned subsidiary of the Company (the "First Merger"), and (ii) immediately following the First Merger and as part of the same overall transaction as the First Merger, Mentari will merge with and into the Second Merger Sub, with the Second Merger Sub surviving such merger (the "Second Merger" and, together with the First Merger, the "Merger").

Days to cover

1.0

Short interest

34.08K

Avg volume

78.9K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)
  negativeGlobeNewswire Inc.· May 19, 2026
• InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
  Benzinga· Feb 23, 2024
• Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
  Benzinga· Feb 22, 2024
• Why BlackBerry Shares Are Trading Lower By Over 5%; Here Are 20 Stocks Moving Premarket
  Benzinga· Dec 21, 2023
• Investment Chief At $48B Global X Forecasts AI Stock Dominance In 2024: Unveils Top Investment Opportunities
  Benzinga· Dec 17, 2023